{
    "clinical_study": {
        "@rank": "13381", 
        "acronym": "MCS-8", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo arm"
            }, 
            {
                "arm_group_label": "MCS\u00ae 15 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "MCS\u00ae 15 mg/day, soft capsule"
            }, 
            {
                "arm_group_label": "MCS\u00ae 30 mg/day", 
                "arm_group_type": "Active Comparator", 
                "description": "MCS\u00ae 30 mg/day, soft capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the effect of MCS\u00ae compared with placebo in reducing the risk of\n      biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of\n      treatment."
        }, 
        "brief_title": "To Evaluate the Effect of MCS\u00ae in Prostate Cancer Prevention", 
        "condition": "1. High-risk Subjects of Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  (1) Four groups of high-risk subjects of prostate cancer. (2) Male subject with age\n             from 50 to 75 years old. (3) No active urinary tract infection (UTI) or bacterial\n             prostatitis. (4) Subject is able to understand and willing to comply with the study\n             procedures and has signed the informed consent form (ICF).\n\n        Exclusion Criteria:\n\n          -  (1) Subjects' elevated PSA is deemed by the investigators solely to inflammation or\n             infection of the prostate.\n\n             (2) Subjects who are or will be taking long-term hormonal agents that may affect the\n             normal physiology of sex hormone function.\n\n             (3) Subjects with a PSA > 10.0 ng/ml. I (4) Subjects with a history of prostate\n             cancer. (5) Subjects are currently taking or planning to take oral bile acid\n             sequestrants.\n\n             (6) Subjects have celiac disease, Crohn's disease, partly removal of the intestinal\n             tract (surgically), or any malabsorption conditions.\n\n             (7) Subject participated in another investigational agent study in the past 30 days\n             or is planning to do so during the study period.\n\n             (8) Subjects are considered ineligible for the study as judged by the investigator.\n\n             (9) Other malignancies except non-melanoma skin cancer."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "702", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042807", 
            "org_study_id": "MCS-8-II-TWN"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MCS\u00ae 15 mg/day", 
                    "MCS\u00ae 30 mg/day"
                ], 
                "intervention_name": "MCS\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "contact": {
                "last_name": "Yeong-Shiau Pu", 
                "phone": "+886 2 23123456"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan"
                }, 
                "name": "Department of Urology, National Taiwan University Hospital"
            }, 
            "investigator": {
                "last_name": "Yeong-Shiau Pu", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS\u00ae in Prostate Cancer Prevention", 
        "overall_contact": {
            "last_name": "Fu-Feng Kuo", 
            "phone": "+886 2 25788621"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Taiwan Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Cumulative biopsy-detectable prostate cancer rate", 
            "safety_issue": "No", 
            "time_frame": "Week 104 (Month 24)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042807"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Health Ever Bio-Tech Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Health Ever Bio-Tech Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}